NFKB1 and cancer: However, treatment with CYLD inhibitors might be limited to acute infections and prolonged CYLD inhibition bears the intrinsic risk of cancer development, since CYLD augments NF-κB-STAT3 crosstalk, which supports development of several neoplasms including hepatocellular carcinoma [48], [49], and Cyld mutations are frequently observed in these tumors [19], [20].